FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 87 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2023:... May 25, 2023 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC December 16, 2022 ESMO awards its first fellowship to support digital and computational pathology September 10, 2025 Load more HOT NEWS Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal Woman Helps Students With Special Needs Achieve Success After Graduation ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps...
